Tag: position

As Consumers Search for the Best Non-Prescription Eye Supplements in 2025, Visium Pro Highlights Clean Label Formulation, GMP Manufacturing, and Ingredient Transparency for Digital Eye Strain and Screen Fatigue Support

Singapore, July 08, 2025 (GLOBE NEWSWIRE) -- Delixy Holdings Limited (the “Company” or “Delixy”), a Singapore-based company engaged in the trading of oil related products, today announced the pricing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares, par value US$0.000005 per share, (“Ordinary Shares”), 1,350,000 of which are being offered by the Company and 650,000 by the selling shareholders Mega Origin Holdings Limited (as to 325,000 Ordinary Shares) and Novel Majestic Limited (as to 325,000 Ordinary Shares) (the “Selling Shareholders”), at a public offering price of US$4.00 per Ordinary Share. The Company is also registering a resale prospectus concurrent with the Offering for the resale of 3,000,000 Ordinary Shares held by Cosmic Magnet Limited, Rosywood Holdings Limited, Dragon Circle Limited and Novel Majestic Limited, Golden Legend Ventures Limited (the “Resale Shareholders”). The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July 9, 2025 under the ticker symbol “DLXY.”

As consumer interest in the best activated charcoal grows, NativePath introduces a clean-label, high-purity formula derived from coconut shells to support bloating, gas, and digestive detox.

Transition Accompanies Strong Revenue Growth, Expanded Profitability, and Strengthened Balance Sheet

-- Company completes refinancing of all existing senior secured debt through a $120 million self-syndicated term loan with leading banks, at an interest rate of 8.3% --

-- Company also completes expansion of its consolidated credit facilities with an additional $33 million second lien term loan with $50 million accordion to support ongoing strategic initiatives --

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All of the securities in the offering are being offered by Cogent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

New 2025 Blueprint Reveals How Households Are Preparing for Water Disruptions With Smart, Off-Grid Technology

The all-new XP Trike2 builds on the award-winning design of the most popular electric tricycle, the XP Trike, with loads of upgrades

In this 2025 product availability update, BRĒZ shares how its legal microdosed THC drinks are redefining the fast-growing functional beverage space—offering adults new access to non-alcoholic, hemp-derived cannabis tonics aligned with the search for the best THC drink alternatives.